Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in Brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The resomelagon (AP1189) Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Hyperinflammation
    • Peptide Agonists
  • Investors
    • Capital Markets Day 2025
    • Investment highlights
    • Word from the CEO
    • Financial Reports
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectus and rights issues
      • 2025
      • 2024
      • 2023
      • 2022
      • Older
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact
May 12, 2016
Non Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

The shareholders of Synact Pharma AB (publ), 559058-4826, are hereby summoned to the Extraordinary General Meeting on Monday 30 May 2016 at 10.30am at Scandic Hotel Klara, Slöjdgatan 7 in Stockholm.

Documents

  • Pressmeddelande – Kallelse till extra bolagsstämma i SynAct Pharma AB (publ)
    12 maj, 2016 Svenska
    pdf
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe